NasdaqGM:KYMRBiotechs
Kymera Therapeutics (KYMR) Is Up 7.0% After Advancing Dual Phase 2b Trials for KT-621
Kymera Therapeutics recently began dosing patients in its BREADTH Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe eosinophilic asthma, while continuing a parallel Phase 2b study in atopic dermatitis.
The paired trials are designed to speed KT-621’s development across multiple Type 2 inflammatory diseases, potentially informing dose selection for future Phase 3 programs.
We’ll now examine how the dual Phase 2b program for KT-621 could influence Kymera’s investment...